Clinical trials: Colon Cancer Stage I
Non-Small Cell Lung Carcinoma, Breast Cancer
A Study of V934/V935 Vaccine in Cancer Participants With Selected Solid Tumors (V934-002)
This is a two-part study to test the safety, tolerability, and immune response for V934/V935 vaccine using a new prime-boost regimen in participants with selected solid tumors.
- Conditions
- Non-Small Cell Lung Carcinoma, Breast Cancer, Melanoma, Upper GI Tract Carcinoma
- Trial name
- NCT00753415
- Testing
- V935, V934-EP
- Volunteers
- 37 people
- Sponsor
- Merck Sharp & Dohme LLC
Unresectable or Metastatic Microsatellite Stable (MSS) Solid Tumor, Microsatellite Stable (MSS) Colon Cancer
Study of PI3Kinase Inhibition (Copanlisib) and Anti-PD-1 Antibody Nivolumab in Relapsed/Refractory Solid Tumors With Expansions in Mismatch-repair Proficient (MSS) Colorectal Cancer
A phase I/II study of PI3Kinase inhibition (copanlisib) and anti-PD-1 antibody nivolumab in relapsed/refractory solid tumors with expansions in mismatch-repair proficient (MSS) colorectal cancer.
- Trial name
- NCT03711058
- Testing
- Copanlisib, Nivolumab
- Where
- United States
- Volunteers
- 48 people
- Sponsor
- Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Gastrointestinal Cancer, Pancreatic Cancer
Administering Peripheral Blood Lymphocytes Transduced With a Murine T-Cell Receptor Recognizing the G12D Variant of Mutated RAS in HLA-A*11:01 Patients
Background: A new cancer therapy takes white blood cells from a person, grows them in a lab, genetically changes them, then gives them back to the person.
- Conditions
- Gastrointestinal Cancer, Pancreatic Cancer, Gastric Cancer, Colon Cancer
- Trial name
- NCT03745326
- Testing
- Cyclophosphamide, Fludarabine, Aldesleukin
- Where
- United States
- Volunteers
- 5 people
- Sponsor
- National Cancer Institute (NCI)
Breast Cancer, Colorectal Cancer
Memantine Hydrochloride in Helping Cancer Survivors Stop Smoking
RATIONALE: Memantine hydrochloride may help people stop smoking by decreasing the symptoms of nicotine withdrawal. PURPOSE: This randomized, pilot phase II trial studies how effective memantine hydrochloride works compared to…
- Conditions
- Breast Cancer, Colorectal Cancer, Lung Cancer, Prostate Cancer
- Trial name
- NCT01535040
- Testing
- memantine hydrochloride
- Where
- United States
- Volunteers
- 130 people
- Sponsor
- Wake Forest University Health Sciences
Colon Adenocarcinoma, Rectal Adenocarcinoma
Nintedanib and Capecitabine in Treating Patients With Refractory Metastatic Colorectal Cancer
This phase I/II trial studies the side effects and best dose of nintedanib when given together with capecitabine and to see how well they work in treating patients with colorectal cancer that has not responded to previous…
- Conditions
- Colon Adenocarcinoma, Rectal Adenocarcinoma, Recurrent Colon Carcinoma, Recurrent Rectal Carcinoma
- Trial name
- NCT02393755
- Testing
- Capecitabine, Laboratory Biomarker Analysis, Nintedanib
- Where
- 2 sites in United States
- Volunteers
- 42 people
- Sponsor
- Roswell Park Cancer Institute
Cancer
BRAF/MEK/EGFR Inhibitor Combination Study in Colorectal Cancer (CRC)
This was a four part, phase I/II study aimed to evaluate the safety, tolerability and efficacy of combination of an anti-EGFR antibody panitumumab (P) either with a BRAF inhibitor (dabrafenib (D); GSK2118436) alone or with the…
- Trial name
- NCT01750918
- Testing
- Dabrafenib, Trametinib, Panitumumab
- Where
- 20 sites in United States, Belgium and 6 more
- Volunteers
- 166 people
- Sponsor
- Novartis Pharmaceuticals
Febrile Neutropenia, Stage 0 Breast Cancer
S1415CD, Trial Assessing CSF Prescribing Effectiveness and Risk (TrACER)
This randomized clinical trial studies prophylactic colony stimulating factor management in patients with breast, colorectal or non-small cell lung cancer receiving chemotherapy and with risk of developing febrile neutropenia.
- Conditions
- Febrile Neutropenia, Stage 0 Breast Cancer, Stage 0 Colorectal Cancer, Stage 0 Non-Small Cell Lung Cancer
- Trial name
- TrACER (NCT02728596)
- Testing
- Preventive Intervention, Quality-of-Life Assessment, Questionnaire Administration
- Where
- 160 sites in United States, Puerto Rico
- Volunteers
- 3,665 people
- Sponsor
- SWOG Cancer Research Network
Breast Cancer, Pancreatic Cancer
Dose Escalation Study MORAb-066 Targeting Tissue Factor (TF)-Expressing Malignancies Including Breast, Pancreatic, Colorectal, NSCLC
This study is a Phase I, first in human, dose-escalation study of MORAb-066, an investigational humanized immunoglobulin G (IgG) monoclonal antibody (mAb) that targets TF-expressing malignancies that include breast, pancreatic…
- Conditions
- Breast Cancer, Pancreatic Cancer, Colorectal Cancer, Carcinoma, Non-Small-Cell Lung
- Trial name
- NCT01761240
- Testing
- MORAb-066
- Where
- 2 sites in United States
- Volunteers
- 27 people
- Sponsor
- Morphotek
Colon Cancer, Colorectal Cancer
Phase I/II Study of Celebrex and EPO906 in Patients With Metastatic Colorectal Cancer
This study is for people with advanced colorectal cancer. This study uses the drugs Celebrex and EPO906. EPO906 is an experimental drug that has not been approved by the FDA.
- Trial name
- NCT00159484
- Testing
- EPO906, Celecoxib
- Where
- United States
- Volunteers
- 75 people
- Sponsor
- University of Southern California
Neoplasms Malignant
A Study of Dalotuzumab + MK-2206, Dalotuzumab + MK-0752, and Dalotuzumab + Ridaforolimus Combination Therapies in Participants With Advanced Cancer (MK-0646-027)
This is an open-label, two-part study to evaluate the safety and tolerability of combination treatment with dalotuzumab + MK-2206, dalotuzumab + MK-0752, or dalotuzumab + ridaforolimus (MK-8669).
- Trial name
- NCT01243762
- Testing
- dalotuzumab, MK-0752, ridaforolimus
- Volunteers
- 47 people
- Sponsor
- Merck Sharp & Dohme LLC
Pancreatic Adenocarcinoma, Ovarian Cancer
Trial Investigating an Immunostimulatory Oncolytic Adenovirus for Cancer
This Phase I/II trial evaluates LOAd703 in patients with cancer (pancreatic, biliary, colorectal or ovarian) together with their standard of care chemotherapy or using gemcitabine immune-conditioning.
- Conditions
- Pancreatic Adenocarcinoma, Ovarian Cancer, Biliary Carcinoma, Colorectal Cancer
- Trial name
- NCT03225989
- Testing
- LOAd703
- Where
- 2 sites in Sweden
- Volunteers
- 47 people
- Sponsor
- Lokon Pharma AB
Metastatic Colorectal Cancer
A Phase I/II Study of Cediranib (AZD2171) in Japanese Metastatic Colorectal Cancer Patients in Combination With FOLFOX
This Study is in two parts, the first part is to make sure that combining a potential new treatment, cediranib (AZD2171), with a standard treatment (FOLFOX) for metastatic colorectal cancer is safe.
- Trial name
- NCT00494221
- Testing
- AZD2171, FOLFOX (5-fluorouracil, Leucovorin, Oxaliplatin)
- Where
- 2 sites in Japan
- Volunteers
- 172 people
- Sponsor
- AstraZeneca
Colorectal Cancer
RAD001, FOLFOX and Bevacizumab in Treatment of Colorectal Carcinoma
RAD001 (everolimus) is a novel oral derivative of rapamycin. RAD001 has been in clinical development since 1996 as an immunosuppressant in solid organ transplantation and has obtained marketing authorization (Certican®) for…
- Trial name
- NCT01047293
- Testing
- RAD001, FOLFOX, Bevacizumab
- Where
- 2 sites in United States
- Volunteers
- 47 people
- Sponsor
- University of Utah
Metastatic Colorectal Cancer
Everolimus and OSI-906 for Patients With Refractory Metastatic Colorectal Cancer
The purpose of this study is to determine the maximum tolerated dose (MTD) of the combination of OSI-906 and everolimus for the treatment of patients with refractory metastatic colorectal cancer.
- Trial name
- NCT01154335
- Testing
- OSI-906, Everolimus
- Where
- 2 sites in United States
- Volunteers
- 18 people
- Sponsor
- SCRI Development Innovations, LLC
Metastatic Colorectal Cancer, MSS
Combined PD-1 and CCR5 Inhibition for the Treatment of Refractory Microsatellite Stable mCRC
This is a monocentric, single arm, prospective, open-label trial of a combination treatment consisting of pembrolizumab and maraviroc in previously treated subjects who have refractory microsatellite stable (MSS) metastatic…
- Trial name
- PICCASSO (NCT03274804)
- Testing
- Pembrolizumab, Maraviroc
- Where
- Germany
- Volunteers
- 20 people
- Sponsor
- University Hospital Heidelberg
Metastatic Colorectal Cancer
A Phase I Trial Evaluating mFOLFOX6 and Avastin With Nexavar as First-Line Treatment for Metastatic Colorectal Cancer
This research study is being performed at approximately 3 sites associated with Accelerated Community Oncology Research Network, Inc. (ACORN). Approximately 45 subjects will take part in this study.
- Trial name
- NCT00779311
- Testing
- sorafenib, bevacizumab, mFOLFOX6 regimen
- Where
- 3 sites in United States
- Volunteers
- 8 people
- Sponsor
- Accelerated Community Oncology Research Network
Urinary Bladder Neoplasms, Colorectal Cancer
A First-in-human Study to Evaluate the Safety and Tolerability of AZD8853 in Participants With Selected Advanced/Metastatic Solid Tumours
A Phase I/IIa First-in-human, Open-label Study to Evaluate the Safety, Pharmacokinetics, Pharmacodynamics, and Preliminary Efficacy of AZD8853 in Participants with Selected Advanced/Metastatic Solid Tumours.
- Conditions
- Urinary Bladder Neoplasms, Colorectal Cancer, Carcinoma, Non-Small-Cell Lung
- Trial name
- NCT05397171
- Testing
- AZD8853, Zirconium-89 crefmirlimab berdoxam
- Where
- 6 sites in United States, Canada
- Volunteers
- 17 people
- Sponsor
- AstraZeneca
Colorectal Cancer
Phase I Study of Dalotuzumab (MK-0646) in Combination With Cetuximab and Irinotecan in Participants With Colorectal Cancer (MK-0646-016)
The purposes of this study were to assess the safety, tolerability, pharmacokinetic interactions, and the Human Anti-Human Antibody of dalotuzumab in combination with cetuximab and irinotecan in participants with advanced or…
- Trial name
- NCT00925015
- Testing
- Dalotuzumab 10 mg/kg, Cetuximab, Irinotecan
- Volunteers
- 20 people
- Sponsor
- Merck Sharp & Dohme LLC
Colorectal Neoplasms, Neoplasms
Study Of Sunitinib Plus FOLFOX In Patients With Solid Tumors
This study determined the maximum tolerated dose and safety of SU011248 (sunitinib malate, SUTENT) in combination with FOLFOX [Leucovorin + Fluorouracil (5-FU) + Oxaliplatin].
- Trial name
- NCT00599924
- Testing
- sunitinib + FOLFOX
- Where
- 3 sites in United States
- Volunteers
- 53 people
- Sponsor
- Pfizer
Locally Advanced Solid Tumor, Metastatic Solid Tumor
Trial of MEK Inhibitor and PI3K/mTOR Inhibitor in Subjects With Locally Advanced or Metastatic Solid Tumors
This research trial is testing a combination of two experimental drugs, MSC1936369B (Mitogen-activated protein extracellular signal-regulated kinase (MEK) Inhibitor) and SAR245409 (Phosphatidylinositol 3-kinase (Pi3K)/Mammalian…
- Conditions
- Locally Advanced Solid Tumor, Metastatic Solid Tumor, Breast Cancer, Non Small Cell Lung Cancer
- Trial name
- NCT01390818
- Testing
- MSC1936369B (pimasertib), SAR245409 (PI3K and mTOR inhibitor)
- Where
- 8 sites in United States, Italy and 1 more
- Volunteers
- 146 people
- Sponsor
- EMD Serono